These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [So that the patients.would be able to move for a long time after first diagnosis of rheumatism. Approach as an emergency!]. Fath R MMW Fortschr Med; 2004 Sep; 146(37):4-5. PubMed ID: 15887690 [No Abstract] [Full Text] [Related]
5. [Anti-TNF: beneficial or hamful for the lung?]. Tritar F; Zendah I; Ben M'rad S; Daghfous H Tunis Med; 2009 Sep; 87(9):607-9. PubMed ID: 20180383 [TBL] [Abstract][Full Text] [Related]
6. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526 [TBL] [Abstract][Full Text] [Related]
7. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Ollendorf DA; Klingman D; Hazard E; Ray S Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156 [TBL] [Abstract][Full Text] [Related]
8. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital. Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328 [TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. Bonafede MM; Gandra SR; Fox KM; Wilson KL J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705 [TBL] [Abstract][Full Text] [Related]
10. [Combination drug therapy in rheumatoid arthritis]. Kawai S Nihon Rinsho; 2005 Jan; 63 Suppl 1():549-55. PubMed ID: 15799416 [No Abstract] [Full Text] [Related]
11. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. Favalli EG; Arreghini M; Arnoldi C; Panni B; Marchesoni A; Tosi S; Pontikaki I Arthritis Rheum; 2004 Apr; 51(2):301-2. PubMed ID: 15077278 [No Abstract] [Full Text] [Related]
13. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431 [TBL] [Abstract][Full Text] [Related]
14. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A; Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000 [TBL] [Abstract][Full Text] [Related]
15. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate. Sweet DD; Isac G; Morrison B; Fenwick J; Dhingra V CJEM; 2007 Jan; 9(1):40-2. PubMed ID: 17391602 [TBL] [Abstract][Full Text] [Related]
16. Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Gremese E; Carletto A; Padovan M; Atzeni F; Raffeiner B; Giardina AR; Favalli EG; Erre GL; Gorla R; Galeazzi M; Foti R; Cantini F; Salvarani C; Olivieri I; Lapadula G; Ferraccioli G; Arthritis Care Res (Hoboken); 2013 Jan; 65(1):94-100. PubMed ID: 22730143 [TBL] [Abstract][Full Text] [Related]
17. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Zink A; Listing J; Kary S; Ramlau P; Stoyanova-Scholz M; Babinsky K; von Hinueber U; Gromnica-Ihle E; Wassenberg S; Antoni C; Herzer P; Kekow J; Schneider M; Rau R Ann Rheum Dis; 2005 Sep; 64(9):1274-9. PubMed ID: 15708884 [TBL] [Abstract][Full Text] [Related]
19. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Blom M; Kievit W; Kuper HH; Jansen TL; Visser H; den Broeder AA; Brus HL; van de Laar MA; van Riel PL Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1335-41. PubMed ID: 20506128 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. Hansen KE; Hildebrand JP; Genovese MC; Cush JJ; Patel S; Cooley DA; Cohen SB; Gangnon RE; Schiff MH J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]